- Home
- CMS vs BIIB Comparison
CMS vs BIIB Comparison
Compare CMS & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMS
- BIIB
- Stock Information
- Founded
- CMS 1987
- BIIB 1978
- Country
- CMS United States
- BIIB United States
- Employees
- CMS N/A
- BIIB N/A
- Industry
- CMS Power Generation
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- CMS Utilities
- BIIB Health Care
- Exchange
- CMS Nasdaq
- BIIB Nasdaq
- Market Cap
- CMS 20.5B
- BIIB 20.5B
- IPO Year
- CMS N/A
- BIIB 1991
- Fundamental
- Price
- CMS $65.66
- BIIB $143.95
- Analyst Decision
- CMS Buy
- BIIB Buy
- Analyst Count
- CMS 14
- BIIB 26
- Target Price
- CMS $69.21
- BIIB $234.79
- AVG Volume (30 Days)
- CMS 1.5M
- BIIB 1.1M
- Earning Date
- CMS 02-06-2025
- BIIB 02-11-2025
- Dividend Yield
- CMS 3.13%
- BIIB N/A
- EPS Growth
- CMS 37.73
- BIIB 10.05
- EPS
- CMS 3.50
- BIIB 11.06
- Revenue
- CMS $7,476,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- CMS $6.24
- BIIB N/A
- Revenue Next Year
- CMS $3.57
- BIIB N/A
- P/E Ratio
- CMS $18.83
- BIIB $12.99
- Revenue Growth
- CMS N/A
- BIIB N/A
- 52 Week Low
- CMS $55.10
- BIIB $139.71
- 52 Week High
- CMS $72.40
- BIIB $251.99
- Technical
- Relative Strength Index (RSI)
- CMS 43.66
- BIIB 38.06
- Support Level
- CMS $63.97
- BIIB $139.71
- Resistance Level
- CMS $68.94
- BIIB $143.50
- Average True Range (ATR)
- CMS 1.22
- BIIB 3.62
- MACD
- CMS 0.15
- BIIB -0.17
- Stochastic Oscillator
- CMS 37.63
- BIIB 23.77
About CMS CMS Energy Corporation
CMS Energy is an energy holding company with three principal businesses. Its regulated utility, Consumers Energy, provides regulated natural gas service to 1.8 million customers and electric service to 1.9 million customers in Michigan. CMS Enterprises is engaged in wholesale power generation, including contracted renewable energy. CMS sold EnerBank in October 2021.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.